PI3K inhibitors in thrombosis and cardiovascular disease

被引:65
|
作者
Durrant, Tom N. [1 ]
Hers, Ingeborg [2 ]
机构
[1] Univ Oxford, Dept Chem, Oxford OX1 3QZ, England
[2] Sch Physiol Pharmacol & Neurosci, Biomed Sci Bldg,Univ Walk, Bristol BS8 1TD, Avon, England
来源
CLINICAL AND TRANSLATIONAL MEDICINE | 2020年 / 9卷 / 01期
关键词
Cardiovascular disease; Thrombosis; Platelets; Phosphoinositide; 3-kinase; PI3K; Phosphoinositides; Cellular signalling; II PHOSPHOINOSITIDE 3-KINASE; REGULATES PLATELET ACTIVATION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PI3K-GAMMA INHIBITION; P110-ALPHA ISOFORM; P110-BETA SUBUNIT; CRYSTAL-STRUCTURE; P2Y(12) RECEPTOR; DOSE-ESCALATION; CELL-MIGRATION;
D O I
10.1186/s40169-020-0261-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate important intracellular signalling and vesicle trafficking events via the generation of 3-phosphoinositides. Comprising eight core isoforms across three classes, the PI3K family displays broad expression and function throughout mammalian tissues, and the (patho)physiological roles of these enzymes in the cardiovascular system present the PI3Ks as potential therapeutic targets in settings such as thrombosis, atherosclerosis and heart failure. This review will discuss the PI3K enzymes and their roles in cardiovascular physiology and disease, with a particular focus on platelet function and thrombosis. The current progress and future potential of targeting the PI3K enzymes for therapeutic benefit in cardiovascular disease will be considered, while the challenges of developing drugs against these master cellular regulators will be discussed.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] PI3K Inhibitors in Cardiovascular Disease
    Eisenreich, Andreas
    Rauch, Ursula
    CARDIOVASCULAR THERAPEUTICS, 2011, 29 (01) : 29 - 36
  • [2] Cardiovascular toxicity of PI3Kα inhibitors
    Sadasivan, Chandu
    Zhabyeyev, Pavel
    Labib, Dina
    White, James A.
    Paterson, D. Ian
    Oudit, Gavin Y.
    CLINICAL SCIENCE, 2020, 134 (19) : 2595 - 2622
  • [3] Therapeutic applications of PI3K inhibitors in cardiovascular diseases
    Ghigo, Alessandra
    Morello, Fulvio
    Perino, Alessia
    Hirsch, Emilio
    FUTURE MEDICINAL CHEMISTRY, 2013, 5 (04) : 479 - 492
  • [4] PI3K and Calcium Signaling in Cardiovascular Disease
    Ghigo, Alessandra
    Laffargue, Muriel
    Li, Mingchuan
    Hirsch, Emilio
    CIRCULATION RESEARCH, 2017, 121 (03) : 282 - 292
  • [5] PI3K inhibitors as potential therapeutics for autoimmune disease
    Ball, Jennifer
    Archer, Sophie
    Ward, Stephen
    DRUG DISCOVERY TODAY, 2014, 19 (08) : 1195 - 1199
  • [6] Imidazopyridazine Inhibitors of PI3Kβ
    Rosse, Gerard
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (12): : 1012 - 1013
  • [7] PI3K INHIBITORS AS NOVEL CANCER THERAPIES: IMPLICATIONS FOR CARDIOVASCULAR MEDICINE
    McLean, B.
    Zhabyeyev, P.
    Pituskin, E.
    Paterson, I.
    Haykowsky, M. J.
    Oudit, G. Y.
    CARDIOLOGY, 2013, 125 : 320 - 320
  • [8] PI3K Inhibitors as Novel Cancer Therapies: Implications for Cardiovascular Medicine
    Mclean, Brent A.
    Zhabyeyev, Pavel
    Pituskin, Edith
    Paterson, Ian
    Haykowsky, Mark J.
    Oudit, Gavin Y.
    JOURNAL OF CARDIAC FAILURE, 2013, 19 (04) : 268 - 282
  • [9] Efficacy of PI3K inhibitors to PI3K mutants in enzyme and cell levels
    Dan, Shingo
    Sugita, Hironobu
    Yamazaki, Kanami
    Yamori, Takao
    CANCER RESEARCH, 2009, 69
  • [10] Horizons broaden for PI3Kδ inhibitors
    Katie Kingwell
    Nature Reviews Drug Discovery, 2014, 13 : 573 - 573